Treating osteoarthritis in older patients with tramadol vs nonsteroidal anti-inflammatory drugs may be associated with an increased mortality rate during the year following treatment initiation.
A “Pain and Stress Management” program for the management of chronic pain, was found to be effective in alleviating pain, diminishing stress, promoting self-management of pain, and ameliorating general well-being.
Transcutaneous electrical nerve stimulation administered during physical activity may effectively alleviate fibromyalgia-associated pain, fatigue, and disease impact in women.
Treatment of active Takayasu arteritis with infliximab may result in remission or in a diminished requirement for glucocorticoids.
Zoledronic acid did not significantly reduce knee pain or bone marrow lesion size overall in patients with knee osteoarthritis over 24 months.
Tofacitinib may provide a fast and prolonged analgesic effect in patients with rheumatoid arthritis or psoriatic arthritis who are unresponsive to csDMARD or to TNFi, as well as in individuals with ankylosing spondylitis.
April 28, 2018 is National Prescription Drug Take Back Day.
Several circulating biomarkers for antineutrophil cytoplasmic antibody-associated vasculitis disease activity and organ involvement were identified using targeted serum proteomics.
Discontinuing denosumab therapy in osteoporosis may increase the risk for vertebral fractures.
Common rheumatoid arthritis drugs methotrexate and biologics, but not prednisolone, may increase the risk for herpes zoster.
